optionally be substituted with one or two hydroxyl groups, C_{1-6}alkyl substituted with -NR^4R^5, C_{1-6}alkyl substituted with –C(=O)-NR^4R^5, –$S(=O)_2$-C_{1-6}alkyl, –$S(=O)_2$-$NR^{14}R^{15}$, C_{1-6}alkyl substituted with -$S(=O)_2$-C_{1-6}alkyl, C_{1-6}alkyl substituted with -NH-$S(=O)_2$-C_{1-6}alkyl, R^6, C_{1-6}alkyl substituted with R^6, C_{1-6}alkyl substituted with –C(=O)-R^6, hydroxyC_{1-6}alkyl substituted with R^6, or C_{1-6}alkyl substituted with –$Si(CH_3)_3$; wherein each R^{1a} is hydrogen; wherein R^{10} and R^{11} each independently represent hydrogen, C_{1-6}alkyl, cyanoC_{1-6}alkyl, C_{1-6}alkyl substituted with –$NR^{14}R^{15}$, C_{1-6}alkyl substituted with –C(=O)-$NR^{14}R^{15}$, haloC_{1-6}alkyl, hydroxyC_{1-6}alkyl, hydroxyhaloC_{1-6}alkyl, C_{1-6}alkoxy, C_{1-6}alkoxyC_{1-6}alkyl wherein each C_{1-6}alkyl may optionally be substituted with one or two hydroxyl groups, R^6, C_{1-6}alkyl substituted with R^6, -C(=O)-R^6, -C(=O)-C_{1-6}alkyl, –C(=O)-hydroxyC_{1-6}alkyl, -C(=O)-haloC_{1-6}alkyl,-C(=O)-hydroxyhaloC_{1-6}alkyl, C_{1-6}alkyl substituted with –$Si(CH_3)_3$, –$S(=O)_2$-C_{1-6}alkyl, –$S(=O)_2$-haloC_{1-6}alkyl, -$S(=O)_2$-$NR^{14}R^{15}$, C_{1-6}alkyl substituted with -$S(=O)_2$-C_{1-6}alkyl, C_{1-6}alkyl substituted with -$S(=O)_2$-haloC_{1-6}alkyl, C_{1-6}alkyl substituted with –$S(=O)_2$-$NR^{14}R^{15}$, C_{1-6}alkyl substituted with –NH-$S(=O)_2$-C_{1-6}alkyl, C_{1-6}alkyl substituted with –NH-$S(=O)_2$-haloC_{1-6}alkyl or C_{1-6}alkyl substituted with –NH-$S(=O)_2$-$NR^{14}R^{15}$.

3. A compound according to claim 1 wherein each R^{1a} is hydrogen.

4. A compound according to any one of the preceding claims wherein R^1 represents C_{1-6}alkyl.

5. A compound according to any one of the preceding claims wherein R^1 represents CH_3- or CD_3-.

6. A compound according to any one of the preceding claims wherein R^2 is independently selected from halogen, cyano, C_{1-4}alkyl, C_{2-4}alkenyl, C_{1-4}alkoxy, hydroxyC_{1-4}alkyl, hydroxyC_{1-4}alkoxy, haloC_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, R^{13}, C_{1-4}alkoxy substituted with R^{13}, -C(=O)-R^{13}, C_{1-4}alkyl substituted with NR^7R^8, C_{1-4}alkoxy substituted with NR^7R^8, -NR^7R^8 and -C(=O)-NR^7R^8.

7. A compound according to claim 6 wherein R^2 represents C_{1-4}alkyloxy.

14. A compound according to claim 10 wherein R^1 represents $-CH_3$, each R^{1a} is hydrogen, n represents an integer equal to 2 and each R^2 represents CH_3O-, R^3 represents $-CH_2CH_2$-CH_2-$NHCH_2CF_3$.

15. A compound according to claim 10 wherein R^1 represents $-CH_3$, each R^{1a} is hydrogen, n represents an integer equal to 2 and each R^2 represents CH_3O-, R^3 represents $-CH_2CH_2NH_2$.

16. A compound according to claim 1 wherein the compound is N-(3,5-dimethoxyphenyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]-N'-(2,2,2-trifluoroethyl)propane-1,3-diamine.

17. A compound according to claim 1 wherein the compound is N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine.

18. A compound according to claim 1 wherein the compound is N-(3,5-dimethoxyphenyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine.

19. A compound as defined in any one of claims 1 to 18 or a pharmaceutically acceptable salt or solvate thereof.

20. A combination of a compound according to any one of the preceding claims with ~~another~~ one or more anticancer agents.


21. A combination according to claim 20 wherein the one or more anticancer agents comprises a kinase inhibitor.

~~21~~22. A product containing as first active ingredient a compound according to any one of claims 1 to 19 and as further active ingredient one or more anticancer agent, as a combined preparation for simultaneous, separate or sequential use in the treatment of patients suffering from cancer.

23. A product according to claim 22 wherein the one or more anticancer agents comprises a kinase inhibitor.

~~22~~24. A process for the preparation of a compound of formula (I) as defined in claim 1, which process comprises:


(i) deprotecting a compound of formula (XXX) wherein P represents a ~~suitable~~ –C(=O)-O-C(CH_3)$_3$- protective group, in the presence of an ~~suitable~~ acid selected from HCl or trifluoroacetic acid,



(XXX)

or

(ii) the reaction of a compound of the formula (IX) or (IX'):




(IX) : R^u is -O-S(=O)$_2$-CH_3

(IX') : R^u is Cl

or a protected form thereof, with an appropriately substituted amine or a reactive derivative thereof, ~~such as for example~~ selected from $NHR^{10}R^{11}$ (X), $NHR^{10}P$ (X-a) wherein P represents a –C(=O)-O-C(CH_3)$_3$ protective group, or a suitable nitrogen containing ring within the definition of R^9 :  (XXI), ~~for example in a~~

~~sealed vessel,~~ in the presence of a ~~suitable~~ base selected from triethylamine, K_2CO_3, Na_2CO_3 and sodium hydride, and/or in the presence or absence of a solvent selected from acetonitrile, tetrahydrofuran, dioxane, N,N-dimethylformamide, 1-methyl-pyrrolidinone, dimethylacetamide and an alcohol; or


(iii) the reaction of a compound of the formula (VI):



(VI)

or a protected form thereof, with a compound of formula W_6-C_{1-6}alkyl-$NR^{10}P$ wherein P represents a ~~suitable~~ –C(=O)-O-$C(CH_3)_3$ protective group and W_6 represents a ~~suitable~~ leaving group selected from halo and –O-$S(=O)_2$-CH_3, in the presence of ~~a suitable base~~sodium hydride, and a ~~suitable~~ solvent selected from N,N-dimethylformamide and N,N-dimethylacetamide, followed by removing P and optionally removing any further protecting group present; or


(iv) the reaction of a compound of the formula (VI):



(VI)

or a protected form thereof, with a compound of formula W_6-C_{1-6}alkyl-NHR^{10} wherein W_6 represents a ~~suitable~~ leaving group selected from halo and –O-$S(=O)_2$-CH_3, in the presence of ~~a suitable base~~sodium hydride, and a ~~suitable~~ solvent selected from N,N-dimethylformamide and N,N-dimethylacetamide; or


(v) the reaction of a compound of formula (XXXVI)



(XXXVI)

with hydrazine in the presence of an ~~suitable solvent~~alcohol; or


(vi) the reaction of a compound of formula (IX-1) wherein R^u represents –O-S(=O)$_2$-CH_3,



(IX-1) (X)

with an intermediate of formula (X) in the presence ~~of a suitable solvent~~acetonitrile; or


(vii) the reaction of a compound of formula (VI)



(VI)

with an intermediate of formula W_{11}-R^{3b} wherein R^{3b} represents optionally substituted C_{2-6}alkynyl and W_{11} represents a ~~suitable~~ leaving group selected from halo and –O-S(=O)$_2$-CH_3, in the presence of ~~a suitable base~~sodium hydride and ~~a suitable solvent~~N,N-dimethylformamide; or


(viii) the reaction of a compound of formula (VIII') wherein R^x and R^y represent C_{1-4}alkyl, and R^z represent C_{1-4}alkyl or phenyl,



(VIII')

with ~~a suitable acid~~trifluoroacetic acid, in the presence of ~~a suitable solvent~~tetrahydrofuran; or


(~~viii~~ix) deprotecting a compound of formula (XXXXII)



(XXXXII)

in the presence of ~~a suitable base~~K_2CO_3 and an alcohol ~~suitable solvent~~; or


(~~ix~~x) the reaction of a compound of formula (VI)



(VI)

with di(C_{1-6}alkyl)vinylphosphonate in the presence of ~~a suitable catalyst~~tri-N-butylphosphine and ~~a suitable solvent~~acetonitrile; or


(xi) deprotecting a compound of formula (XXXXI) wherein P represents a –O-C(=O)-C_{1-6}alkyl protective group



(XXXXI)

in the presence of ~~a suitable base~~K_2CO_3 and an alcohol ~~suitable solvent~~; or


(xii) the reaction of a compound of formula (XIX) wherein R^{3a} represents optionally substituted C_{1-6}alkyl with a compound of formula (III)



(XIX) (III)

in the presence of a ~~suitable~~ catalyst selected from tetrakis(triphenyl)phosphine palladium and $Pd_2(dba)_3$ (tris(dibenzylideneacetone) dipalladium (0)); 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl; ~~a suitable ligand,~~ a ~~suitable~~ base selected from Na_2CO_3 and K_3PO_4; ~~,~~ and a ~~suitable~~ solvent selected from ethylene glycol dimethylether, dioxane and water; or


(xiii) the reaction of a compound of formula (XX) wherein R^{3a} represents optionally substituted C_{1-6}alkyl, with a compound of formula (XIV) wherein W_5 represents halo



(XX) (XIV)

in the presence of a ~~suitable~~ catalyst selected from palladium (II) acetate and $Pd_2(dba)_3$ (tris(dibenzylidene acetone) dipalladium (0)); ~~,~~ a ~~suitable~~ ligand selected from 2-dicyclohexylphosphino-tris-isopropyl-biphenyl and 1,1'-[1,1'-binaphthalene]-2,2'-diylbis[1,1-diphenylphosphine]; sodium tert-butoxide, ~~a suitable base,~~ ; and ~~a suitable solvent~~ethylene glycol dimethylether; or


(~~xiii~~xiv) the reaction of a compound of formula (XXXI)



(XXXI)


with W_8-CN, wherein W_8 represents ~~a suitable leaving group~~halo, in the presence of ~~a~~ $NaHCO_3$ ~~suitable base~~ and a ~~suitable~~ solvent selected from water and dioxane; or


(~~xiv~~xv) the reaction of a compound of formula (XXXV)



(XXXV)

with a ~~suitable~~ base selected from *N,N*-diisopropylethylamine and triethylamine in the presence of an alcohol ~~suitable solvent~~; or


(xvi) deprotecting a compound of formula (XXVI) wherein P represents a ~~suitable~~ protective group selected from –O-Si(CH$_3$)$_2$(C(CH$_3$)$_3$) and ,



(XXVI)

in the presence of an ~~suitable~~ acid selected from HCl and trifluoroacetic acid, or ~~a suitable de-silylating agent~~tetrabutyl ammonium fluoride, and a ~~suitable~~ solvent selected from an alcohol and tetrahydrofuran; or


(xvii) the reaction of a compound of formula (XXIX) with a compound of formula (XXI)



(XXIX)

in the presence of ~~suitable~~ peptide coupling reagents selected from 1-hydroxy-benzotriazole and 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide HCl; or


(xviii) the reaction of a compound of formula (XXIX)



(XXIX)

with NHR^4R^5 in the presence of ~~suitable~~ peptide coupling reagents selected from 1-hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide HCl and ~~a suitable base~~triethylamine, and ~~a suitable solvent~~dichloromethane; or


(~~xviii~~xix) reacting the below compound



:

with NHR^7R^8 in the presence of ~~a suitable base~~ K_2CO_3 and ~~a suitable solvent~~tetrahydrofuran; or

(~~xviii~~xx) deprotecting the below compound



in the presence of hydrazine monohydrate and an alcohol ~~suitable solvent~~;

wherein R^1, R^{1a}, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11} and n are as defined in claim 1; and optionally thereafter converting one compound of the formula (I) into another compound of the formula (I).

~~23~~25. A pharmaceutical composition comprising a compound of formula (I) as defined in any one of claims 1 to 19.

~~24~~26. A compound as defined in any one of claims 1 to 19 for use in therapy.

~~25~~27. A compound as defined in any one of claims 1 to 19 for use in the prophylaxis or treatment of a disease state or condition selected from multiple myeloma, myeloproliferative disorders, endometrial cancer, prostate cancer, bladder cancer, lung cancer, ovarian cancer, breast cancer, gastric cancer, colorectal cancer, and oral squamous cell carcinoma.

~~26~~28. A compound as defined in any one of claims 1 to 19 for use in the prophylaxis or treatment of cancer.

~~27~~29. A compound for use as defined in claim ~~26~~ 28 wherein the cancer is mediated by a FGFR kinase.

~~28~~30. A compound as defined in claim ~~26~~ 28 for use in the treatment of cancer wherein the cancer is selected from lung cancer, in particular NSCLC, squamous cell carcinoma, liver cancer, kidney cancer, breast cancer, colon cancer, colorectal cancer, and prostate cancer.

~~29~~31. Use of a compound as defined in any one of claims 1 to 19 for the manufacture of a medicament for the prophylaxis or treatment of cancer.

~~30. Use according to claim 29 wherein the cancer is mediated by a FGFR kinase.~~

~~31~~32. Use according to claim ~~29~~ 31 for the treatment of cancer wherein the cancer is selected from multiple myeloma, myeloproliferative disorders, endometrial cancer, prostate cancer, bladder cancer, lung cancer, ovarian cancer, breast cancer, gastric cancer, colorectal cancer, and oral squamous cell carcinoma.

~~32~~33. Use according to claim ~~29~~ 31 for the treatment of cancer wherein the cancer is selected from lung cancer, in particular NSCLC, squamous cell carcinoma, liver cancer, kidney cancer, breast cancer, colon cancer, colorectal cancer, prostate cancer.

34. Use according to claim 31 wherein the cancer is multiple myeloma.

35. Use according to claim 34 wherein the cancer is t(4;14) translocation positive multiple myeloma.

36. Use according to claim 31 wherein the cancer is bladder cancer.

37. Use according to claim 36 wherein the cancer is bladder cancer with a FGFR3 chromosomal translocation.

38. Use according to claim 36 wherein the cancer is bladder cancer with a FGFR3 point mutation.

39. Use according to claim 31 wherein the cancer is a tumour with a mutant of FGFR1, FGFR2, FGFR3 or FGFR4.

40. Use according to claim 31 wherein the cancer is a tumour with a gain-of-function mutant of FGFR2 or FGFR3.

41. Use according to claim 31 wherein the cancer is a tumour with over-expression of FGFR1.

42. Use according to claim 31 wherein the cancer is urothelial carcinoma.

43. Use according to claim 31 for the treatment of liver cancer where expression of its ligand FGF19 is frequently elevated.

44. Use of a compound as defined in any one of claims 1 to 19 for the manufacture of a medicament for the prophylaxis or treatment of a carcinoma wherein the carcinoma is a carcinoma of the bladder, breast, colon, kidney, epidermis, liver, lung, oesophagus, head and neck, gall bladder, ovary, pancreas, stomach, gastrointestinal (also known as gastric) cancer, cervix, endometrium, thyroid, prostate, or skin, a hematopoietic tumour of lymphoid lineage; a hematopoietic tumour of myeloid lineage; multiple myeloma; thyroid follicular cancer; a tumour of mesenchymal origin; a tumour of the central or peripheral nervous system; melanoma; seminoma; teratocarcinoma; osteosarcoma; xeroderma pigmentosum; keratoctanthoma; thyroid follicular cancer; or Kaposi's sarcoma.

45. Use of a compound as defined in claim 44 for the treatment of glioblastoma multiforme.

46. A compound according to any one of claims 1 to 19 for use in the treatment of cancer wherein said compound is used in combination with one or more anticancer agents.

47. A compound according to any one of claims 1 to 19 for use in the treatment of cancer wherein said compound is used in combination with one or more anticancer agents and wherein the one or more anticancer agents comprises a kinase inhibitor.